**Background of H. pylori Antibodies**
*Helicobacter pylori (H. pylori)* is a gram-negative bacterium colonizing the human stomach, linked to gastritis, peptic ulcers, and gastric cancer. Detection of *H. pylori* antibodies plays a critical role in diagnosing infections, particularly in non-invasive serological testing. These antibodies, primarily IgG and IgA, are produced in response to bacterial antigens like urease and cytotoxin-associated gene A (CagA). IgG antibodies, the most commonly measured, indicate current or past infection, persisting months after eradication. IgA antibodies may reflect active mucosal immune response but are less sensitive.
Serological assays (e.g., ELISA) are cost-effective and non-invasive, useful for initial screening or epidemiological studies. However, antibody tests cannot distinguish active from resolved infections, limiting utility in post-treatment monitoring. They also show variable sensitivity due to antigenic diversity across strains.
Despite limitations, antibody detection remains valuable in regions with high *H. pylori* prevalence and limited access to endoscopic or urea breath tests. Recent advancements focus on improving antigen specificity, including recombinant proteins or immunoblot assays. Research also explores antibody profiles as biomarkers for predicting disease severity, such as gastric cancer risk associated with CagA-positive strains. Overall, *H. pylori* antibody testing bridges diagnostic and research needs in understanding bacterial pathogenesis and host immunity.